Breathe Well Live Well
Condition: Anesthesia
Interventions: Drug: lidocaine-epinephrine; Drug: Topicaine gel
Sponsor: David Grant U.S. Air Force Medical Center
Enrolling by invitation – verified February 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Researchers demonstrate clinical efficacy of gallopamil in severe asthma patients
News-Medical.net A team of Inserm researchers from the Cardio-Thoracic Research Centre of Bordeaux (Inserm/University of Bordeaux and Bordeaux University Hospital) has demonstrated the clinical efficacy of gallopamil in 31 patients with severe asthma. This chronic … |
View full post on asthma – Google News
Conditions: Rhinitis; Rhinoconjunctivitis; Asthma
Interventions: Biological: DP/MG/14-1; Biological: DP/MG/14-2
Sponsor: Laboratorios Leti, S.L.
Recruiting – verified January 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: QGE031; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Not yet recruiting – verified January 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Biological: Benralizumab; Biological: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified December 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh; Drug: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh; Drug: Symbicort Turbuhaler 320/9 ug/inhalation 4 inh; Drug: Symbicort Turbuhaler 320/9 ug/inhalation 1inh; Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh; Drug: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh; Drug: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh; Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
Sponsor: Orion Corporation, Orion Pharma
Not yet recruiting – verified December 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler; Drug: Placebo inhalation powders via ELLIPTA inhaler; Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler; Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler; Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
Sponsor: GlaxoSmithKline
Not yet recruiting – verified November 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Vitamin D improves corticosteroid efficacy and attenuates its side-effects in an animal model of asthma.
Can J Physiol Pharmacol. 2014 Nov 3;:1-9
Authors: Mehta AA, Agrawal AD, Appanna V, Chaudagar KK
Abstract
The subacute use of corticosteroids has side-effects such as glucose intolerance, dyslipidemia, anxiety, and depression, which could be halted with vitamin D, which is an immunomodulatory vitamin. Thus, we aimed to study the anti-asthmatic efficacy and side-effects profile of vitamin D, the corticosteroid dexamethasone, and their combination on ovalbumin-induced airway inflammation in rats. For this, 2 different doses of vitamin D (50 IU/kg, daily for 2 weeks, or and 60000 IU/kg, bolus dose, by intraperitoneal injection (i.p.)) were administered in combination with dexamethasone (2.5 mg/kg, i.p., for 2 weeks) prior to challenge with ovalbumin. At the end of the therapy, the asthmatic parameters such as differential white blood cell counts, serum levels of immunoglobulin E, bronchoalveolar lavaged fluid, and interleukin-5, as well as serum levels of nitric oxide were significantly increased after allergen challenges in asthmatic rats as compared with the controls. Such increases were significantly attenuated by monotherapy with vitamin D and with combination therapy of vitamin D and dexamethasone, where the combination therapy was superior to the monotherapy. Dexamethasone-induced hyperglycemia, hyperlipidemia, and behavioral abnormalities in the allergic rats were attenuated with vitamin D. The daily dose was better for controlling serum levels of immunoglobulin E than the bolus dose, whereas the bolus was superior for reducing dexamethasone-induced psychotropic abnormalities. There were no significant changes in other parameters between the daily and the bolus dose. In conclusion, a daily dose of vitamin D in combination with dexamethasone is more efficacious for treating asthma in allergic rats than monotherapy.
PMID: 25429688 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
AB Science: Web conference on masitinib in asthma – Safety and Efficacy Update
GlobeNewswire (press release) Paris, France, Nov. 25, 2014 (GLOBE NEWSWIRE) — AB Science SA (NYSE Euronext – FR0010557264 – AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web … |
View full post on asthma – Google News
Condition: Oral Corticosteroid Dependent Asthma
Interventions: Biological: Tralokinumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days